Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$363,678
in 3 filings, $327K under 10b5-1 plans

Net −$363,678. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-06-01 Cole Douglas G. Director Grant or award +4,216 26,564
2023-06-01 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +12,649 12,649
2022-06-02 Cole Douglas G. Director Grant or award +5,986 22,348
2022-06-02 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +17,959 17,959
2021-06-02 Cole Douglas G. Director Grant or award +2,074 5,327
2021-06-02 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +6,222 6,222
2021-06-01 Cole Douglas G. Director Exercise or conversion +3,253 3,253
2021-06-01 Cole Douglas G. Director Exercise or conversion · Restricted Stock Units −3,253 0
2020-06-03 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +15,183 15,183
2020-06-03 Cole Douglas G. Director Grant or award · Restricted Stock Units +3,253 3,253
2019-05-30 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +27,245 27,245
2018-06-13 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +27,830 27,830
2017-12-07 Cole Douglas G. Director Grant or award · Stock Option (right to buy) +47,165 47,165

Page 1 of 1 · 13 trades